Lantheus Holdings (LNTH)

$65.2

-0.01

(-0.02%)▲

Market is closed - opens 7 PM, 26 Apr 2024

Insights on Lantheus Holdings

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 319.94M → 353.99M (in $), with an average increase of 9.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 131.95M → 103.38M (in $), with an average decrease of 21.7% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 34.1% return, outperforming this stock by 57.3%

Performance

  • $63.77
    $65.25
    $65.20
    downward going graph

    2.19%

    Downside

    Day's Volatility :2.27%

    Upside

    0.08%

    downward going graph
  • $50.20
    $100.85
    $65.20
    downward going graph

    23.01%

    Downside

    52 Weeks Volatility :50.22%

    Upside

    35.35%

    downward going graph

Returns

PeriodLantheus HoldingsSector (Health Care)Index (Russel 2000)
3 Months
23.3%
0.5%
0.0%
6 Months
-0.76%
11.7%
0.0%
1 Year
-23.19%
6.2%
2.2%
3 Years
165.15%
13.5%
-23.0%

Highlights

Market Capitalization
4.4B
Book Value
$11.91
Earnings Per Share (EPS)
4.65
PE Ratio
13.74
PEG Ratio
0.61
Wall Street Target Price
97.5
Profit Margin
25.2%
Operating Margin TTM
42.45%
Return On Assets TTM
21.28%
Return On Equity TTM
51.73%
Revenue TTM
1.3B
Revenue Per Share TTM
18.99
Quarterly Revenue Growth YOY
34.5%
Gross Profit TTM
581.7M
EBITDA
566.0M
Diluted Eps TTM
4.65
Quarterly Earnings Growth YOY
1.19
EPS Estimate Current Year
6.58
EPS Estimate Next Year
6.67
EPS Estimate Current Quarter
1.45
EPS Estimate Next Quarter
1.51

Analyst Recommendation

Buy
    93%Buy
    6%Hold
    0
    0%Sell
Based on 15 Wall street analysts offering stock ratings for Lantheus Holdings(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
14
13
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 49.54%

Current $65.20
Target $97.50

Company Financials

FY18Y/Y Change
Revenue
343.4M
↑ 3.62%
Net Income
40.5M
↓ 67.16%
Net Profit Margin
11.8%
↓ 25.43%
FY19Y/Y Change
Revenue
347.3M
↑ 1.15%
Net Income
31.7M
↓ 21.84%
Net Profit Margin
9.12%
↓ 2.68%
FY20Y/Y Change
Revenue
339.4M
↓ 2.28%
Net Income
-13.5M
↓ 142.55%
Net Profit Margin
-3.97%
↓ 13.09%
FY21Y/Y Change
Revenue
425.2M
↑ 25.28%
Net Income
-71.3M
↑ 429.05%
Net Profit Margin
-16.76%
↓ 12.79%
FY22Y/Y Change
Revenue
935.1M
↑ 119.91%
Net Income
28.1M
↓ 139.38%
Net Profit Margin
3.0%
↑ 19.76%
FY23Y/Y Change
Revenue
1.3B
↑ 38.65%
Net Income
326.7M
↑ 1063.86%
Net Profit Margin
25.2%
↑ 22.2%
Q3 FY22Q/Q Change
Revenue
239.3M
↑ 6.96%
Net Income
61.2M
↑ 42.21%
Net Profit Margin
25.59%
↑ 6.34%
Q4 FY22Q/Q Change
Revenue
263.2M
↑ 9.98%
Net Income
-119.2M
↓ 294.64%
Net Profit Margin
-45.29%
↓ 70.88%
Q1 FY23Q/Q Change
Revenue
300.8M
↑ 14.29%
Net Income
-2.8M
↓ 97.64%
Net Profit Margin
-0.93%
↑ 44.36%
Q2 FY23Q/Q Change
Revenue
321.7M
↑ 6.95%
Net Income
94.1M
↓ 3453.44%
Net Profit Margin
29.26%
↑ 30.19%
Q3 FY23Q/Q Change
Revenue
319.9M
↓ 0.55%
Net Income
132.0M
↑ 40.18%
Net Profit Margin
41.24%
↑ 11.98%
Q4 FY23Q/Q Change
Revenue
354.0M
↑ 10.64%
Net Income
103.4M
↓ 21.66%
Net Profit Margin
29.2%
↓ 12.04%
FY18Y/Y Change
Total Assets
439.8M
↑ 14.58%
Total Liabilities
368.8M
↑ 2.29%
FY19Y/Y Change
Total Assets
405.9M
↓ 7.71%
Total Liabilities
291.3M
↓ 21.02%
FY20Y/Y Change
Total Assets
869.8M
↑ 114.28%
Total Liabilities
355.6M
↑ 22.07%
FY21Y/Y Change
Total Assets
863.8M
↓ 0.69%
Total Liabilities
399.3M
↑ 12.3%
FY22Y/Y Change
Total Assets
1.3B
↑ 52.96%
Total Liabilities
874.1M
↑ 118.89%
FY23Y/Y Change
Total Assets
1.7B
↑ 24.97%
Total Liabilities
835.3M
↓ 4.44%
Q3 FY22Q/Q Change
Total Assets
1.1B
↑ 8.1%
Total Liabilities
457.9M
↑ 2.55%
Q4 FY22Q/Q Change
Total Assets
1.3B
↑ 20.56%
Total Liabilities
874.1M
↑ 90.9%
Q1 FY23Q/Q Change
Total Assets
1.3B
↑ 2.12%
Total Liabilities
903.8M
↑ 3.39%
Q2 FY23Q/Q Change
Total Assets
1.3B
↓ 0.86%
Total Liabilities
785.1M
↓ 13.13%
Q3 FY23Q/Q Change
Total Assets
1.5B
↑ 13.75%
Total Liabilities
822.9M
↑ 4.81%
Q4 FY23Q/Q Change
Total Assets
1.7B
↑ 8.51%
Total Liabilities
835.3M
↑ 1.51%
FY18Y/Y Change
Operating Cash Flow
61.2M
↑ 11.71%
Investing Cash Flow
-19.1M
↑ 17.31%
Financing Cash Flow
-4.7M
↓ 65.29%
FY19Y/Y Change
Operating Cash Flow
80.4M
↑ 31.36%
Investing Cash Flow
-22.1M
↑ 15.31%
Financing Cash Flow
-78.9M
↑ 1589.82%
FY20Y/Y Change
Operating Cash Flow
16.4M
↓ 79.6%
Investing Cash Flow
-4.9M
↓ 77.73%
Financing Cash Flow
-21.9M
↓ 72.29%
FY21Y/Y Change
Operating Cash Flow
53.9M
↑ 228.84%
Investing Cash Flow
3.7M
↓ 174.98%
Financing Cash Flow
-39.3M
↑ 79.92%
FY22Y/Y Change
Operating Cash Flow
281.8M
↑ 422.63%
Investing Cash Flow
-276.5M
↓ 7608.74%
Financing Cash Flow
311.7M
↓ 892.46%
Q3 FY22Q/Q Change
Operating Cash Flow
93.6M
↑ 28.89%
Investing Cash Flow
-6.1M
↑ 40.23%
Financing Cash Flow
-2.0M
↓ 2.59%
Q4 FY22Q/Q Change
Operating Cash Flow
105.4M
↑ 12.59%
Investing Cash Flow
-264.7M
↑ 4246.86%
Financing Cash Flow
317.8M
↓ 16324.6%
Q1 FY23Q/Q Change
Operating Cash Flow
108.5M
↑ 2.99%
Investing Cash Flow
-44.5M
↓ 83.19%
Financing Cash Flow
-8.7M
↓ 102.73%
Q2 FY23Q/Q Change
Operating Cash Flow
-32.3M
↓ 129.74%
Investing Cash Flow
-20.7M
↓ 53.5%
Financing Cash Flow
-4.1M
↓ 53.27%

Technicals Summary

Sell

Neutral

Buy

Lantheus Holdings is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Lantheus Holdings
Lantheus Holdings
10.98%
-0.76%
-23.19%
165.15%
165.15%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-2.41%
27.65%
34.11%
39.49%
77.94%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-0.12%
5.13%
-5.51%
13.36%
13.36%
Zoetis Inc.
Zoetis Inc.
-7.43%
-2.98%
-11.32%
-9.68%
48.39%
Viatris Inc.
Viatris Inc.
-1.12%
27.59%
26.04%
-15.35%
-29.8%
Catalent, Inc.
Catalent, Inc.
-0.82%
42.09%
27.6%
-51.77%
23.97%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Lantheus Holdings
Lantheus Holdings
13.74
13.74
0.61
6.58
0.52
0.21
NA
11.91
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
56.26
56.26
0.44
4.78
0.13
0.09
NA
22.61
Haleon Plc Spon Ads
Haleon Plc Spon Ads
29.82
29.82
1.69
0.45
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
29.5
29.5
2.58
5.8
0.5
0.13
0.01
10.9
Viatris Inc.
Viatris Inc.
231.0
231.0
NA
2.78
0.0
0.03
0.04
17.05
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.48
-0.3
-0.01
NA
20.41
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Lantheus Holdings
Lantheus Holdings
Buy
$4.4B
165.15%
13.74
25.2%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.1B
77.94%
56.26
13.23%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$38.1B
13.36%
29.82
9.28%
Zoetis Inc.
Zoetis Inc.
Buy
$68.3B
48.39%
29.5
27.43%
Viatris Inc.
Viatris Inc.
Hold
$13.7B
-29.8%
231.0
0.35%
Catalent, Inc.
Catalent, Inc.
Hold
$10.1B
23.97%
211.02
-31.77%

Institutional Holdings

  • BlackRock Inc

    12.35%

  • Vanguard Group Inc

    10.17%

  • HHG PLC

    5.76%

  • State Street Corporation

    3.50%

  • FMR Inc

    3.40%

  • AllianceBernstein L.P.

    2.87%

Company Information

lantheus holdings, inc. (nasdaq: lnth) is the parent company of lantheus medical imaging, inc. (lmi), which is a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. lmi provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. lmi’s key products include the echocardiography contrast agent definity® vial for (perflutren lipid microsphere) injectable suspension; technelite® (technetium tc99m generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and xenon (xenon xe 133 gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. the company is headquartered in north billerica, massachusetts with offices in puerto rico and canada. for more information, visit www.lantheus.com.

Organization
Lantheus Holdings
Employees
834
CEO
Mr. Brian A. Markison
Industry
Health Technology

Discover More

FAQs